Enanta advances zelicapavir to registrational Phase 2b/3 trial in high-risk adults with RSV; pediatric Phase 2b planned

ENANTA PHARMACEUTICALS INC

Registrational Phase 2b/3 trial in high-risk adults (≥75 yrs, COPD, CHF) to start 4Q 2026; Phase 2b topline data expected 2027.
Phase 2b pediatric trial (28 days-36 months) to start 3Q 2026; topline data expected 2027; conducted with Penta Foundation and Chiang Mai University.
FDA End-of-Phase 2 meeting successful; trial design includes 800mg oral zelicapavir once daily for 7 days vs placebo.
Enanta estimates global market opportunity for oral RSV antiviral >$2B; US addressable population >3M patients.
No available treatment options for RSV; zelicapavir could be first antiviral therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.